Knowledge Distillery

Safe, effective vaccines against coronavirus disease 2019 (COVID-19) are urgently needed in children younger than 12 years of age. In this article the…

Adults in receipt of a single dose of ChAdOx1 or BNT162b2 were enrolled at 12 UK sites and randomly assigned to receive concomitant administration of…

In this trial, done at 43 centres in France, the authors randomly assigned patients receiving invasive mechanical ventilation for up to 72 h with…

The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human adenovirus type 26 vector encoding full-length SARS-CoV-2 spike protein in a…

CoV2 preS dTM is a stabilised pre-fusion spike protein vaccine produced in a baculovirus expression system being developed against SARS-CoV-2.

In this phase 1, double-blind, placebo-controlled, block-randomised trial the authors aimed to assess the safety and immunogenicity of an…

A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020.

Data on the efficacy of hydroxychloroquine or lopinavir-ritonavir for the treatment of high-risk outpatients with COVID-19 in developing countries are…

High-flow nasal oxygen is recommended as initial treatment for acute hypoxemic respiratory failure and is widely applied in patients with COVID-19.

The emergence of SARS-CoV-2 variants threatens progress toward control of the Covid-19 pandemic.

LY-CoV555, a neutralising monoclonal antibody, has been associated with a decrease in viral load and frequency of hospitalisations or emergency…

Recent data suggest that complications and death from COVID-19 may be related to high viral loads.